platform

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

1. 41/100

   Ultrasensitive SERS nanoprobe-based multiplexed digital sensing platform for the simultaneous quantification of Alzheimer's disease biomarkers

   ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Biosensors & bioelectronics · 2025-01-28 · Biomarkers

   Alzheimer's disease (AD) is a severe neurodegenerative disease that requires early diagnosis to manage its progression.

   • Biomarkers
   • Digital Tools
2. 57/100

   Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer's Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms

   ✓ Peer-reviewed alzhub usefulness score 57 out of 100. International journal of molecular sciences · 2024-04-23 · Biomarkers

   We compared the clinical and analytical performance of Alzheimer's disease (AD) plasma biomarkers measured using the single-molecule array (Simoa) and Lumipulse platforms.

   • Biomarkers
   • Diagnosis
3. 64/100

   Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform

   ✓ Peer-reviewed alzhub usefulness score 64 out of 100. The journal of prevention of Alzheimer's disease · 2024-01-01 · Biomarkers

   Plasma p-tau217 measured using the Lumipulse platform shows promise as an accurate biomarker of preclinical AD pathology.

   • Biomarkers
   • Early Stage
   • Diagnosis
4. 48/100

   Comparative Analysis of Alzheimer's Disease Cerebrospinal Fluid Biomarkers Measurement by Multiplex SOMAscan Platform and Immunoassay-Based Approach

   ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of Alzheimer's disease : JAD · 2022-01-01 · Biomarkers

   Our data indicate that SOMAscan performs as well as immunoassay approaches for NfL, Neurogranin, VILIP-1, and sTREM2.

   • Biomarkers
5. 40/100

   Towards point-of-care diagnosis of Alzheimer's disease: Multi-analyte based portable chemiresistive platform for simultaneous detection of β-amyloid (1-40) and (1-42) in plasma

   ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Biosensors & bioelectronics · 2021-05-04 · Biomarkers

   Label-free simultaneous detection of Alzheimer's disease (AD) specific biomarkers Aβ40 and Aβ42 peptides on a single platform using polypyrrole nanoparticle-based chemiresistive biosensors is reported here.

   • Biomarkers
   • Brain Scans
6. 41/100

   An Update on Blood-Based Markers of Alzheimer's Disease Using the SiMoA Platform

   ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Neurology and therapy · 2019-12-12 · Biomarkers

   The development of blood-based biomarkers of Alzheimer's disease (AD) pathology as tools for screening the general population, and as the first step in a multistep process to determine which non-demented individuals are at greatest risk of developing AD dementia, is essential.

   • Biomarkers
   • Brain Biology
7. 48/100

   Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms

   ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of Alzheimer's disease : JAD · 2018-01-01 · Biomarkers

   This study confirms strong concordance between CSF biomarkers and PET Aβ-amyloid status is independent of immunoassay platform, supporting their utility as biomarkers in clinical practice for the diagnosis of AD and for participant enrichment in clinical trials.

   • Biomarkers
   • Brain Scans

All topic tags with their study counts